Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

• Những tác giả chính: Abhijeet Jakate (Tác giả), Ramesh Boinpally (Tác giả), Matthew Butler (Tác giả), Wendy Ankrom (Tác giả), Marissa F Dockendorf (Tác giả), Antonia Periclou (Tác giả)
• Định dạng: Sách
• Được phát hành: SAGE Publishing, 2021-08-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.

Background: Ubrogepant is metabolized by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Objective: To assess effects of multiple-dose moderate-strong CYP3A4 and strong P-gp inhibitors and inducers on ubrogepant pharmacokinetic (PK) parameters. Methods: Two phase 1, open-label...